All In Biotech

Drug Trial Radar · NCT03713658

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Oct 18, 2018

Primary completion

Dec 2, 2019

Study completion Dec 2, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan healthcare facilities with mental healthcare capabilities.

Conditions

  • Schizophrenia

Interventions

  • Risperidone 3 mgDrug

    Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.

  • Paliperidone Palmitate 50 mg eq.Drug

    Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.

  • Paliperidone Palmitate 75 mg eq.Drug

    Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.

  • Paliperidone Palmitate 100 mg eq.Drug

    Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.

  • Paliperidone Palmitate 150 mg eq.Drug

    Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.

  • Paliperidone Palmitate 175 mg eq.Drug

    Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.

  • Paliperidone Palmitate 263 mg eq.Drug

    Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.

  • Paliperidone Palmitate 350 mg eq.Drug

    Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.

  • Paliperidone Palmitate 525 mg eq.Drug

    Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Successful Completion of Study ProceduresTime frame: Up to Week 46
  2. Percentage of Participants With Successful Delivery of Risperidone/PP1M/PP3M for the Duration of the StudyTime frame: Up to Week 46
  3. Percentage of Participants With Successful Administration of Risperidone/PP1M/PP3M Throughout the StudyTime frame: Up to Week 46
  4. Quality of Life as Assessed by World Health Organization Quality of Life Scale Brief Version (WHO QoL-BREF) Total ScoreTime frame: Up to Week 46
  5. Clinician Satisfaction as Assessed by Clinician Satisfaction Rating Scale ScoreTime frame: Up to Week 46

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CARAES Ndera Neuro-Psychiatric Hospital

    Kigali, Rwanda

  • Ruhengeri Referral Hospital, Public Hospital

    Musanze District, Rwanda

  • Kibungo Referral Hospital

    Ngoma District, Rwanda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.